Agenus (NASDAQ:AGEN) Share Price Passes Above 200 Day Moving Average of $2.31

Shares of Agenus Inc. (NASDAQ:AGENGet Rating) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.31 and traded as high as $2.36. Agenus shares last traded at $2.29, with a volume of 1,931,379 shares traded.

Analyst Upgrades and Downgrades

Separately, TheStreet downgraded shares of Agenus from a “c-” rating to a “d” rating in a research report on Friday, May 27th.

Agenus Trading Down 0.9 %

The company has a market capitalization of $634.29 million, a P/E ratio of 22.30 and a beta of 1.17. The business’s 50-day simple moving average is $2.68 and its 200 day simple moving average is $2.31.

Agenus (NASDAQ:AGENGet Rating) last released its earnings results on Tuesday, August 9th. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. Agenus had a net margin of 3.07% and a return on equity of 11.65%. During the same period in the prior year, the company posted ($0.37) EPS. As a group, sell-side analysts predict that Agenus Inc. will post -0.7 EPS for the current fiscal year.

Institutional Trading of Agenus

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC purchased a new position in shares of Agenus in the fourth quarter worth approximately $32,000. U.S. Capital Wealth Advisors LLC purchased a new position in shares of Agenus in the first quarter worth approximately $25,000. Qube Research & Technologies Ltd purchased a new position in shares of Agenus in the fourth quarter worth approximately $40,000. Bank of Nova Scotia purchased a new position in shares of Agenus in the first quarter worth approximately $31,000. Finally, Coastal Bridge Advisors LLC purchased a new position in Agenus during the fourth quarter valued at approximately $42,000. 51.89% of the stock is currently owned by institutional investors.

Agenus Company Profile

(Get Rating)

Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

Further Reading

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.